Intrathecal baclofen in subjects with spastic hemiplegia: Assessment of the antispastic effect during gait

Archives of Physical Medicine and Rehabilitation

Volumn 84, Issue 5, 2003, Pages 643-650

  Rémy Néris, Olivier ^a,c   Tiffreau, Vincent ^a   Bouilland, Stiphane ^a   Bussel, Bernard ^b  

^a Department of Physical Medicine   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c Centre J Calve Fondation Hopale   (France)

Author keywords

Baclofen; Gait; Hemiplegia; Muscle spasticity; Rehabilitation

Indexed keywords

BACLOFEN;

ADULT; ANKLE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ELECTROMYOGRAPHY; FEMALE; GAIT; HEMIPARESIS; HUMAN; JOINT MOBILITY; KINEMATICS; KNEE; LEG MUSCLE; MALE; QUADRICEPS FEMORIS MUSCLE; SCORING SYSTEM; TRICEPS SURAE MUSCLE; WALKING SPEED;

EID: 0037653598     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(02)04906-7     Document Type: Article

References (42)

1. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125-7.
2. Azouvi P, Roby-Brami A, Biraben A, Thiebaut JB, Thurel C, Bussel B. Effect of intrathecal baclofen on the monosynaptic reflex in humans: evidence for a postsynaptic action. J Neurol Neurosurg Psychiatry 1993;56:515-9.
3. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418-22.
4. Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 1997;244:160-6.
5. Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg 1997; 87:415-9.
6. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001; 32:2099-109.
7. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000;46:603-9; discussion 9-12.
8. Gerszten PC, Albright AL, Barry MJ. Effect on ambulation of continuous intrathecal baclofen infusion. Pediatr Neurosurg 1997; 27:40-4.
9. Bodensteiner J. The management of cerebral palsy: subjectivity and a conundrum. J Child Neurol 1996;11:75-6.
10. Tabary JC, Tabary C, Tardieu C, Tardieu G, Goldspink G. Physiological and structural changes in the cat's soleus muscle due to immobilization at different lengths by plaster casts. J Physiol (Lond) 1972;224:231-44.
11. Dietz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain 1981;104: 431-49.
12. Lance JW. Symposium synopsis. In: Koella W, editor. Spasticity: disordered motor control. Chicago: Year Book Medical; 1980; p 185-230.
13. Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil 1999;80:13-9.
14. Sahrmann SA, Norton BJ. The relationship of voluntary movement to spasticity in the upper motor neuron syndrome. Ann Neurol 1977;2:460-5.
15. Knutsson E, Martensson A. Dynamic motor capacity in spastic paresis and its relation to prime mover dysfunction, spastic reflexes and antagonist co-activation. Scand J Rehabil Med 1980; 12:93-106.
16. Crenna P, Frigo C. Monitoring gait with a vector diagram technique in spastic patients. In: Delwaide PJ, Young RR, editors. Clinical neurophysiology of spasticity. Amsterdam: Elsevier; 1985. p 109-24.
17. Crenna P, Inverno M. Objective detection of pathophysiological factors contributing to gait disturbance in supraspinal lesions. In: Fedrizzi E, Avanzini G, Crenna P, editors. Motor development in children. London: John Libbey; 1994. p 103-18.
18. Crenna P. Spasticity and 'spastic' gait in children with cerebral palsy. Neurosci Behav Rev 1998;22:571-8.
19. Frigo C, Crenna P, Jensen LM. Moment-angle relationship at lower limb joints during human walking at different velocities. J Electromyogr Kinesiol 1996;6:177-90.
20. Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Am J Phys Med Rehabil 1999;78:247-54.
21. Edrich T, Riener R, Quintern J. Analysis of passive elastic joint moments in paraplegics. IEEE Trans Biomed Eng 2000;47:1058-65.
22. Lin CJ, Guo LY, Su FC, Chou YL, Cherng RJ. Common abnormal kinetic patterns of the knee in gait in spastic diplegia of cerebral palsy. Gait Posture 2000;11:224-32.
23. Brunner R, Krauspe R, Romkes J. [Torsion deformities in the lower extremities in patients with infantile cerebral palsy: pathogenesis and therapy] [German]. Orthopade 2000;29:808-13.
24. Latash ML, Penn RD, Corcos DM, Gottlieb GL. Effects of intrathecal baclofen on voluntary motor control in spastic paresis. J Neurosurg 1990;72:388-92.
25. Meythaler JM, Steers WD, Tuel SM, Cross LL, Haworth CS. Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. Am J Phys Med Rehabil 1992;71:321-7.
26. Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadley MN. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 2001;82:155-61.
27. Penn RD, Gianino JM, York MM. Intrathecal baclofen for motor disorders. Mov Disord 1995;10:675-7.
28. Steinwender G, Saraph V, Scheiber S, Zwick EB, Uitz C, Hackl K. Intrasubject repeatability of gait analysis data in normal and spastic children. Clin Biomech (Bristol, Avon) 2000;15:134-9.
29. De Quervain IA, Simon SR, Leurgans S, Pease WS, McAllister D. Gait pattern in the early recovery period after stroke. J Bone Joint Surg Am 1996;78:1506-14.
30. Kerrigan D, Roth R, Riley P. The modelling of spastic paretic stiff-legged gait based on actual kinematic data. Gait Posture 1998;7:117-24.
31. Corston RN, Johnson F, Godwin-Austen RB. The assessment of drug treatment of spastic gait. J Neurol Neurosurg Psychiatry 1981;44:1035-9.
32. Orsnes GB, Sorensen PS, Larsen TK, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101:244-8.
33. Hesse S, Jahnke M, Schreider C, Mauritz K. Gait symmetry and functional walking performance in hemiparetic patients prior to and after a 4-week rehabilitation programme. Gait Posture 1993; 1:166-71.
34. Kerrigan DC, Frates EP, Rogan S, Riley PO. Spastic paretic stiff-legged gait: biomechanics of the unaffected limb. Am J Phys Med Rehabil 1999;78:354-60.
35. Lundberg A. Maximal aerobic capacity of young people with spastic cerebral palsy. Dev Med Child Neurol 1978;20:205-10.
36. Mattsson E, Andersson C. Oxygen cost, walking speed, and perceived exertion in children with cerebral palsy when walking with anterior and posterior walkers. Dev Med Child Neurol 1997;39: 671-6.
37. Suzuki N, Shinohara T, Kimizuka M, Yamaguchi K, Mita K. Energy expenditure of diplegic ambulation using flexible plastic ankle foot orthoses. Bull Hosp Jt Dis 2000;59(2):76-80.
38. Tantucci C, Massucci M, Piperno R, Grassi V, Sorbini CA. Energy cost of exercise in multiple sclerosis patients with low degree of disability. Mult Scler 1996;2:161-7.
39. Dietz V, Ketelsen UP, Berger W, Quintern J. Motor unit involvement in spastic paresis. Relationship between leg muscle activation and histochemistry. J Neurol Sci 1986;75:89-103.
40. Pierrot-Deseilligny E. Electrophysiological assessment of the spinal mechanisms underlying spasticity. Electroencephalogr Clin Neurophysiol Suppl 1990;41:264-73.
41. O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. Brain 1996;119:1737-49.
42. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner 1964;192:540-2.